Research progress of bonemodifying agents in the treatment of bone metastases

doi:10.3760/cma.j.issn.1673422X.2014.03.021

Abstract

Abstract: Bonemodifying agents (BMA) is a series drugs to alleviate the pain, pathological fractures, spinal cord compression, hypercalcemia, bonerelated events which induced by bone metastases. Bisphosphonate drugs and denosumab are two dominant kinds of BMA at present. It has been proved that BMA is used in bone metastases patients with bone destruction, as adjuvant therapy for chemotherapy and radiotherapy, which can significantly improve the efficacy and prolong the survival of patients. In addition, some traditional Chinese medcine can effectively relieve a series of related symptoms caused by bone metastases and improve prognosis. Choosing right medication in clinical work can maximize the reduction of pain caused by bonerelated events and improve the quality of life of patients.

Key words: Neoplasm metastases, Diphosphonates, Denosumab

SUN Shan-Shan, ZHANG Yue-Meng, GAO Ying-Jie, GAO Wen-Cang. Research progress of bonemodifying agents in the treatment of bone metastases[J]. Journal of International Oncology, 2014, 41(3): 226-228.

References

［1］ FigueroaMagalhes MC, Miller RS. Bonemodifying agentsas adjuvant therapy for earlystage breast cancer［J］. Oncology (Williston Park), 2012, 26(10):955962. ［2］ Russell RG. Bisphosphonates: the first 40 years［J］. Bone, 2011, 49(1): 219. ［3］ Sallami S, Ben Rhouma S, Cherif K, et al. The role of bisphosphonate in the treatment of bone metastases from prostate cancer［J］. Tunis Med, 2012, 90(7):507511. ［4］ LopezOlivo MA, Shah NA, Pratt G, et al. Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and metaanalysis［J］. Support Care Cancer, 2012, 20(11):29852998. ［5］ Valachis A, Polyzos NP, Coleman RE, et al. Adjuvant Therapy With Zoledronic Acid in Patients With Breast Cancer: A Systematic Review and MetaAnalysis［J］. Oncologist, 2013, 18(4):353361. ［6］ Murphy L, McCarthy J, McCrate F, et al. Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre［J］. Support Care Cancer, 2013, 21(6):15571560. ［7］ Sabry NA, Habib EE. Zoledronic acid and clodronate in the treatment of malignant bone metastases with hypercalcaemia; efficacy and safety comparative study［J］. Med Oncol, 2011, 28(2):584590. ［8］ Wang F, Chen W, Chen H, et al. Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bonemetastases［J］. Med Oncol, 2013, 30(3): 657657. ［9］ Wang Y, Tao H, Yu X, et al. Clinical significance of zoledronic acid and strontium89 in patients with asymptomatic bone metastases from nonsmallcell lung cancer［J］. Clin Lung Cancer, 2013, 14(3): 254260. ［10］ Drooger JC, van der Padt A, Sleijfer S, et al. Denosumab in breast cancer treatment［J］. Eur J Pharmacol, 2013, 717(13):1219. ［11］ Peters S, Meylan E. Targeting receptor activator of nuclear factorkappa B as a new therapy for bone metastasis in nonsmall cell lung cancer［J］. Curr Opin Oncol, 2013, 25(2):137144. ［12］ Paller CJ, Carducci MA, Philips GK. Management of bone metastases in refractory prostate cancerrole of denosumab［J］. Clin Interv Aging, 2012, 7:363372. ［13］ GomezVeiga F, PonceReixa J, MartinezBreijo S, et al. Advances in Prevention and Treatment of Bone Metastases in Prostate Cancer. Role of RANK/RANKL Inhibition［J］. Actas Urol Esp, 2013, 37(5):292304. ［14］ Cleeland CS, Body JJ, Stopeck A, et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, doubleblind study of denosumab and zoledronic acid［J］. Cancer, 2013, 119(4):832838. ［15］ Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletalrelated events: a combined analysis of 3 pivotal, randomised, phase 3 trials［J］. Eur J Cancer, 2012, 48(16):30823092. ［16］侯恩仁. 补肾填精壮骨方治疗恶性肿瘤骨转移21例［J］. 中国民族民间医药, 2010, 19(3):9191. ［17］蔡亚丽．中西医结合治疗骨转移癌性疼痛80例［J］. 山东中医杂志， 2010， 29(8)：555556. ［18］王向春，裴俊文. 益肾化浊汤治疗骨转移癌痛临床研究［J］. 中医学报, 2012, 27(5):532533. ［19］冯宇, 杨青青, 王海明, 等. 补肾壮骨法治疗乳腺癌骨转移的临床研究［J］. 中华中医药学刊, 2012, 30(6):14121414

[1]	Teng Fei, Cui Guimin, Shi Hongyun, Liu Miaoling, Li Yanhong. Clinical observation of radiotherapy combined with temozolomide in non-small cell lung cancer patients with brain metastases [J]. Journal of International Oncology, 2017, 44(4): 271-273.
[2]	刘梦实，杨海燕，李红梅. Bevacizumab in the treatment of non-small-cell lung cancer with brain metastases [J]. Journal of International Oncology, 2017, 44(11): 864-865.
[3]	HOU Su-Juan, LIU Yuan-Shui, ZHAO Wen-Hua. Efficacy of cryoablation combined with zoledronic acid sequential therapy for bone metastases pain [J]. Journal of International Oncology, 2015, 42(4): 264-268.
[4]	LIN Gang, WANG Zhun, XU Ya-Ping. Application of stereotactic body radiotherapy in extracranial metastases [J]. Journal of International Oncology, 2014, 41(11): 820-823.
[5]	SUN Shan-Shan, GAO Wen-Cang-. Research progress of bone metabolic markers [J]. Journal of International Oncology, 2013, 40(7): 546-548.